Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
25–50
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Healthy male subjects, 25 to 50 years of age, inclusive; healthy status is defined by absence of evidence of any active or chronic disease
Body mass index (BMI) 18 to 30 kg/m2 inclusive
Male subjects with female partners of child-bearing potential must use two methods of contraception, one of which must be a barrier method (i.e. condom), for the duration of the study and for 30 days after the last dose
You may not be if
History of any clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardio-vascular, endocrinological, haematological or allergic disease, metabolic disorder, cancer or cirrhosis
History of clinically significant hypersensitivity or allergic drug reactions
Any suspicion or history of alcohol abuse and/or consumption of other drugs of abuse
Regular smoker (\> 5 cigarettes, \> 1 pipeful or \> 1 cigar per day)
Positive for hepatitis B, hepatitis C, or HIV infection
Evidence of significant cardiovascular disease or disorder
Participation in an investigational drug or device study within 3 months prior to first administration of the study drug or within 6 times the elimination half-life, whichever is longer
Previous inclusion in a research and/or medical protocol or any clinical procedures involving nuclear medicine, PET, occupational exposure to ionizing radiation or radiological investigations with significant exposure to radiation, excluding dental X-ray and common X-rays of chest or extremities
Subject has any condition that would prevent an MRI from accurately or safely being performed \[eg, claustrophobia, cardiac pacemaker, metallic implants or clips\]
Subject unable to lie on his back in the PET or MRI scanner for a period of 90 minutes
Contraindication for arterial cannulation
Unsuitable veins for repeated venipuncture
Clareo Health | A PET Study With RO5545965 in Healthy Male Volunteers
